Guide-specific loss of efficiency and off-target reduction with Cas9 variants
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkad702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Liang Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, CRISPR-Associated Protein 9. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
High-fidelity clustered regularly interspaced palindromic repeats (CRISPR)-associated protein 9 (Cas9) variants have been developed to reduce the off-target effects of CRISPR systems at a cost of efficiency loss. To systematically evaluate the efficiency and off-target tolerance of Cas9 variants in complex with different single guide RNAs (sgRNAs), we applied high-throughput viability screens and a synthetic paired sgRNA–target system to assess thousands of sgRNAs in combination with two high-fidelity Cas9 variants HiFi and LZ3. Comparing these variants against wild-type SpCas9, we found that ∼20% of sgRNAs are associated with a significant loss of efficiency when complexed with either HiFi or LZ3. The loss of efficiency is dependent on the sequence context in the seed region of sgRNAs, as well as at positions 15–18 in the non-seed region that interacts with the REC3 domain of Cas9, suggesting that the variant-specific mutations in the REC3 domain account for the loss of efficiency. We also observed various degrees of sequence-dependent off-target reduction when different sgRNAs are used in combination with the variants. Given these observations, we developed GuideVar, a transfer learning-based computational framework for the prediction of on-target efficiency and off-target effects with high-fidelity variants. GuideVar facilitates the prioritization of sgRNAs in the applications with HiFi and LZ3, as demonstrated by the improvement of signal-to-noise ratios in high-throughput viability screens using these high-fidelity variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- The Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Liang Zhang
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
Zitieren
APA
Zhang, L., He, W., Fu, R., Wang, S., Chen, Y., & Xu, H. (2023). Guide-specific loss of efficiency and off-target reduction with Cas9 variants. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad702
Vancouver
Zhang L, He W, Fu R, Wang S, Chen Y, Xu H. Guide-specific loss of efficiency and off-target reduction with Cas9 variants. Nucleic Acids Research. 2023. doi:10.1093/nar/gkad702
BibTeX
@article{Zhang2023,
author = {Zhang, Liang and He, Wei and Fu, Rongjie and Wang, Shuyue and Chen, Yiwen and Xu, Han},
title = {Guide-specific loss of efficiency and off-target reduction with Cas9 variants},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkad702}
}
EUVIMED